Hepatitis E - Pipeline Review, H1 2018

June 2018 | 28 pages | ID: HF918034AA4EN
Global Markets Direct

Abstracts

Hepatitis E - Pipeline Review, H1 2018

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis E - Pipeline Review, H1 2018, provides an overview of the Hepatitis E (Infectious Disease) pipeline landscape.

Hepatitis E is a serious disease caused by the hepatitis E virus (HEV). The virus targets the liver. Symptoms include yellowing of the skin, dark urine, fever, fatigue, joint pain, nausea, a loss of appetite, pain in the abdomen. It is caused by drinking water contaminated by fecal matter.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatitis E - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Hepatitis E (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatitis E (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis E and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 1, 2 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Hepatitis E (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis E (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Hepatitis E (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Hepatitis E (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Hepatitis E (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis E (Infectious Disease)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Hepatitis E (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Hepatitis E (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Hepatitis E - Overview
Hepatitis E - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Hepatitis E - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hepatitis E - Companies Involved in Therapeutics Development
Cadila Healthcare Ltd
Chongqing Zhifei Biological Products Co Ltd
CPL Biologicals Pvt Ltd
Gilead Sciences Inc
Hepatitis E - Drug Profiles
hepatitis E vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hepatitis E vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hepatitis E vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hepatitis E vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sofosbuvir - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hepatitis E - Dormant Projects
Hepatitis E - Product Development Milestones
Featured News & Press Releases
Mar 27, 2013: Changchun Company Initiates Phase I Study Of New Hepatitis E Recombinant Vaccine
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Hepatitis E, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Hepatitis E - Pipeline by Cadila Healthcare Ltd, H1 2018
Hepatitis E - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H1 2018
Hepatitis E - Pipeline by CPL Biologicals Pvt Ltd, H1 2018
Hepatitis E - Pipeline by Gilead Sciences Inc, H1 2018
Hepatitis E - Dormant Projects, H1 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development for Hepatitis E, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

COMPANIES MENTIONED

Cadila Healthcare Ltd
Chongqing Zhifei Biological Products Co Ltd
CPL Biologicals Pvt Ltd
Gilead Sciences Inc